A few years ago, following early encouraging data, two KRAS G12C inhibitors came into the spotlight at the American Society of Clinical Oncology meeting in Chicago. While new therapies are not exceptional in pharma, what made these drugs special was that scientists had been trying to develop a drug specifically for this target for a very long time.

With updated data on both drugs, one of which is already approved, the market has been forecasting billion-dollar sales for these therapies in the near future. In this month’s issue, we take a look at their clinical significance and whether the hype is warranted.

Also, in this issue, features delve into the early research on nanorobots and how they could address drug delivery challenges, and how foreign direct investments in nucleic acid therapies have burgeoned in the recent past despite a general investment slowdown due to the pandemic.

All this, and the latest pharma industry news, comment, data, and analysis from GlobalData.

Read the latest issue of Pharma Technology Focus for all this and more news, insights, data and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a new issue is available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData